Analysts expect Senseonics Holdings, Inc. (NASDAQ:SENS) to announce sales of $5.08 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Senseonics’ earnings, with the highest sales estimate coming in at $7.16 million and the lowest estimate coming in at $4.04 million. Senseonics posted sales of $2.95 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 72.2%. The company is expected to announce its next earnings results on Thursday, May 9th.

According to Zacks, analysts expect that Senseonics will report full year sales of $27.79 million for the current fiscal year, with estimates ranging from $27.47 million to $28.10 million. For the next fiscal year, analysts expect that the company will post sales of $68.12 million, with estimates ranging from $55.92 million to $80.31 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Senseonics.

Shares of NASDAQ SENS opened at $2.58 on Monday. Senseonics has a 1-year low of $2.15 and a 1-year high of $5.29.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

Featured Article: Can systematic risk be avoided?

Get a free copy of the Zacks research report on Senseonics (SENS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with's FREE daily email newsletter.